OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 13,860 Cr.
- Current Price ₹ 1,210
- High / Low ₹ 2,250 / 1,057
- Stock P/E 453
- Book Value ₹ 515
- Dividend Yield 0.00 %
- ROCE 5.52 %
- ROE 3.34 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -17.7% over last 3 years.
- Debtor days have increased from 86.2 to 105 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE Allcap BSE 250 SmallCap Index
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 21 | 128 | 39 | 172 | 1,445 | 1,419 | |
| 93 | 132 | 199 | 254 | 978 | 1,025 | |
| Operating Profit | -71 | -4 | -161 | -82 | 467 | 395 |
| OPM % | -334% | -3% | -415% | -48% | 32% | 28% |
| 1 | -128 | -526 | -143 | -94 | 5 | |
| Interest | 16 | 46 | 48 | 89 | 166 | 133 |
| Depreciation | 34 | 53 | 66 | 76 | 274 | 276 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -9 |
| Tax % | 0% | -0% | 0% | 0% | -73% | |
| -121 | -231 | -800 | -391 | -18 | 20 | |
| EPS in Rs | -1.57 | 1.77 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 124% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| TTM: | 157% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -19% |
| 3 Years: | -18% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,893 |
| 386 | 1,182 | 864 | 571 | 772 | 1,295 | |
| 96 | 248 | 365 | 459 | 1,005 | 814 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,013 |
| 633 | 1,231 | 1,361 | 863 | 6,118 | 6,286 | |
| CWIP | 431 | 490 | 334 | 188 | 218 | 173 |
| Investments | 0 | 0 | 4 | 20 | 16 | 20 |
| 195 | 722 | 314 | 356 | 1,305 | 1,535 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,013 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | |
| -207 | -692 | -68 | 511 | -201 | |
| 381 | 1,162 | 118 | -391 | 412 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 |
| Inventory Days | 87 | 615 | 258 | 222 | |
| Days Payable | 762 | 420 | 163 | 147 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 180 |
| Working Capital Days | -2,392 | -1,331 | -6,745 | -877 | -58 |
| ROCE % | -3% | -12% | -12% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Q3 FY26: Revenue INR2,903m; EBITDA INR173m; PAT loss INR472m; >INR700 crore capex; semaglutide approval delays.
-
Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations, 2011 And Regulation 7(2) Of SEBI (PIT) Regulations, 2015
28 Jan - Tenshi acquired 200,000 shares (0.17%) of OneSource on January 28, 2026.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Jan
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jan - Newspaper advertisement- Unaudited financial results of the Company for the quarter ended December 31, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
24 Jan - Addendum correcting Jan 23, 2026 press release: FY28 guidance is $400M organic, $500M including acquisitions.
Annual reports
Concalls
-
Jan 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.